





































































Dialysis after graft loss: a Swiss experience 
 
 
Marco Bonani1*, Rita Achermann2*, Harald Seeger1, Michael Scharfe3, Thomas Müller1, Stefan 
Schaub3, Isabelle Binet4, Uyen Huynh-Do5, Suzan Dahdal5, Dela Golshayan6, Karine Hadaya7, Rudolf 
Wüthrich1, Thomas Fehr8, Stephan Segerer1,9, and the Swiss Transplantation Cohort Study (STCS) 
 
1Division of Nephrology, University Hospital Zürich, Switzerland  
2Department Transplant Immunology and Nephrology, University Basel Hospital, Switzerland 
3Clinical Trial Unit, Department of Clinical Research, University Basel Hospital, Switzerland 
4Division of Nephrology/Transplantation Medicine, Kantonsspital St. Gallen, Switzerland 
5Department of Nephrology and Hypertension, University of Bern, Switzerland 
6Transplantation Center, CHUV University Hospital, Lausanne, Switzerland 
7Division of Nephrology, Geneva University Hospitals, Geneva, Switzerland 
8Department of Internal Medicine, Kantonsspital Graubünden, Chur, Switzerland 




Stephan Segerer, MD 
eMBA UZH 




Tel:     ++41 628389574 
Fax:    ++41 628386552 
 
Short title: Dialysis after graft loss 
 
Keywords:  Kidney transplantation, graft loss, dialysis, immunosuppression, allograft 
nephrectomy 
 








Renal transplantation is the treatment of choice for suitable patients with end-stage renal 
disease. Patients who return to dialysis after graft loss (DAGL), have a high early morbidity 
and mortality. As there are major differences in the treatment protocols of patients returning 
to dialysis, we used data from the Swiss Transplant Cohort Study (STCS) to describe current 
management and outcome in Switzerland.  
We included 1499 patients who received a renal allograft between May 2008 and end of 
December 2014. 78 patients lost the graft during follow up, of those 41 allografts were lost 
within one year after transplantation (53%). Eleven patients died within 30 days after 
allograft loss. Patient survival was 86%, 81% and 74% after 30, 90 and 365 days after graft 
loss respectively. After graft loss, 90% of the patients started hemodialysis (31% with 
catheters, 54% with native fistulae, and 10% with vascular grafts). Starting with a permanent 
vascular access was associated with a decreased mortality (hazard ratio 0.32). At the time 
of graft loss, the majority of patients were on triple immunosuppressive therapy, which was 
reduced to double immunosuppression during the following year. After allograft 
nephrectomy, immunosuppression was significantly reduced. One year after graft loss 31 
patients in the early and 16 in the late loss group had been nephrectomized. Three years 
after graft loss, 37% of the patients with early and 9% with late graft loss received another 
allograft, of those 20 out of 23 had an allograft nephrectomy.  
In summary, we present a detailed analysis of the STCS of patients after allograft failure. 
Our data illustrate a high mortality, a high number of allograft nephrectomies and re-
transplantations. Patients commencing hemodialysis with a catheter had a significantly 
higher mortality compared to patients with a definitive vascular access. The role of 
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immunosuppression reduction and allograft nephrectomy as interdependent factors for 





Dialysis and renal transplantation are currently integrated into a long-term treatment plan for 
patients with renal failure. A comprehensive pre-dialysis evaluation reduces the mortality of 
incident dialysis patients and increases the chance of receiving an allograft [1, 2]. Data 
suggests that the pre-dialysis treatment might be suboptimal for patients with dialysis after 
graft loss (DAGL) as compared to incident dialysis patients [3]. 
In the first year after transplantation about 7% cadaveric donor recipients and 3% of the 
living donor recipients return to dialysis (USRDS, 2016). The period after the loss of a renal 
allograft is very important for the patient, as mortality and morbidity in the first months, as 
well as in the long run are particularly high [1, 2]. The death rate of US allograft recipients 
was found to be 6.4/100 patient-years on the waiting list, and in the peritransplant period it 
was higher with 8.2/100 patient-years [4]. Initiation of dialysis after allograft loss was 
associated with a strikingly high death rate of 17.9/100 patient-years, more than twice the 
number of the period after major surgery [4]. Little information is available from European 
transplant centers about the current treatment of patients returning to dialysis.  
Here we have used the data from the Swiss Transplantation Cohort Study (STCS) to define 
patients who lost the allograft and collected data about dialysis, immunosuppressive 
treatment, allograft nephrectomy and death after the loss of the allograft. 
 
Materials and Methods 
Study Population 
For the present study, we analyzed patients enrolled in the STCS, a nationwide, longitudinal 
multicenter study. All patients who received a renal allograft in Switzerland between Mai 
between 2008 and December 2014 were included. All patients were at least 18 years of age, 
6 
 
and had given informed consent. Patients with primary non-function or additional organs 
transplanted were excluded. Overall 1499 patients received a renal allograft (first allograft 
or re-transplantation) of whom 78 lost their allograft at least once until January 2015. As we 
considered only the first graft-loss of a patient within STCS, 2 graft losses were excluded.   
Data analyzed for the present study are part of the STCS data collection for the period up 
to graft loss. Thereafter, no further data was collected by the STCS, thus information on type 
of dialysis, the vascular access, immunosuppressive therapy, allograft nephrectomy and 
available information on cause of death after graft loss were collected in addition by each 
allograft center for patients with graft loss. Data were collected up to the time point of death 
or re-transplantation of the patient or time point of data collection (July 2015 until January 
2016).  The data collection was approved by the Zurich ethical committee for research 
involving human subjects (KEK-ZH-Nr. 2015-0445). 
 
Statistical analysis  
For the analysis, the patients with graft loss were divided into two groups depending on 
whether the graft loss occurred within one year after transplantation or later. To describe the 
course after graft loss, a multistate model with initial state dialysis after graft loss, transient 
state nephrectomy and absorbing states death or re-transplantation was set up (R-library 
mstate). Confidence intervals for the probabilities to be in a particular state at a selected 
time point were derived with the bootstrap method.  
To compare mortality between patients with and without graft loss, a cox proportional hazard 
model with a time dependent covariate for graft loss was set up. As the risk of death depends 
on the time after graft loss, a categorical time dependent covariate was incorporated with 
categories no graft loss, 0-30, 31-90, 91-180, more than 180 days after graft loss. To test 
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whether the model adequately represents the data, a test for violation of cox proportional 
hazard assumptions was performed and Schoenfeld residuals plots were inspected.  
All analyses were performed using R Statistical Software Version 3.3.1 (Core Team. R: A 




Patient characteristics  
Characteristics of the study population, separated into patients with and without graft loss, 
were illustrated in Figure 1 and Table 1. A total of 78 patients lost at least one renal allograft.  
Patients with graft loss were further divided into an early graft loss group (41 patients, 53%) 
with a graft loss within 365 days after transplantation and a late group with a graft loss later 
than 365 days after transplantation (37 patients, 47%). The median follow up time for 
patients without graft loss was 1445 (Inter Quartile Range (IQR) 729, 1908) days and for 
patients with graft loss 1186 (IQR 463, 2244) days up to time point of graft loss (Table 2). 
There were no significant differences in the baseline characteristics according to age, type 
of dialysis, reason for transplantation and comorbidities between patients with and without 
graft loss at the time of transplantation. In the group with allograft loss, there were 
significantly less patients who received an allograft from living donors and less patients who 
received a preemptive allograft (p< 0.001). 
 
Mortality of patients after graft loss 
After graft loss, patients were followed for a median of 446 days in the early group (IQR 137, 
925) and for 790 days for the late group (IQR 441, 1468).  For each patient and point of 
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time, one of the following statuses were assigned: on dialysis without nephrectomy, on 
dialysis with nephrectomy, death or re-transplanted. The result of this multistate model is 
shown in Figure 2 and in Table 2. The percentage of patients in each state is illustrated in 
Figure 3. 
During the observation period 23 (29%) patients died: 13 patients who lost the allograft early 
and 10 patients in the group with allograft loss after 1 year (Figure 2). In the early group 6 
out of 41 patients died within 30 days, in the late group 5 out of 37. Six patients died after a 
nephrectomy with four in the early and two in the late group. The transition probability for 
dying after nephrectomy was 12%. 
A Kaplan Meier curve for death after graft loss (Figure 4) shows, that immediately after graft 
loss the risk of dying is high, survival rate was 86% [CI 95% 76-92], 81% [CI 95% 70-88] and 
74% [CI 95% 63-83] after 30, 90 days and 1 year after graft loss respectively.  
A cox proportional hazard model adjusted for age and diabetes with a categorical time 
dependent variable for the time since graft loss showed a hazard ratio (HR) of 87.7 (CI 95% 
45-179) for the period 0-30 days after graft loss compared to patients with no graft loss 
(Figure 4). For the period 180 days after graft loss, HR decreased to 2.7 (CI 95% 1.2-6.2). 
No significant difference was observed between early and late graft loss group. Causes of 
death were cardiovascular disease (n = 8/23), infectious complications (n = 4/23), and 9/23 
died of other reasons (not further specified). Mortality was associated with age (HR per 10 
years 1.7, CI 95% 1.4-2.0, p value < 0.0001) and diabetes status (HR 2.5, CI 95% 1.7-3.7, 





A total of 50 nephrectomies were performed in the 78 patients, 31 in the early group and 19 
in the late group. In the early group all surviving patients were nephrectomized with a single 
exception. 19 of 31 (61%) nephrectomies were performed at time of graft loss in the early 
group, while only 3 of 19 (16%) allografts were removed immediately in the late group. Half 
a year after graft loss, 76% (CI 95% 59-86) of patients in the early and 35% (CI 95% 20-51) 
in the late group were nephrectomized as shown by the cumulative incidence graph adjusted 
for competing risk re-transplantation and death (Figure 5). As some individuals died, only 
5% patients of the early group were on dialysis without nephrectomy half a year after graft 
loss compared to 49 % in the late group. Thereafter, no further nephrectomies were 
performed. At two years after graft loss, only 24% of patients were left without nephrectomy 
in the late group as illustrated by the multistate model (Figure 3). The reasons for 
nephrectomy are listed in Table 3. Infection and rejection were similar in number as causes 
given for nephrectomy. 
 
Retransplantation  
The earliest retransplantation was performed 327 days after graft loss. Retransplantation 
was associated with the time to graft loss. Patients with early graft loss were more likely to 
have a retransplantation within the first 3 years. Three years after graft loss, 25.4% of 
patients in the early group (CI 95% 15.6 -37.4) were re-transplanted and 8.8 % (CI 95% 0.0 
- 24.8) in the late group. Most of the retransplanted patients underwent a nephrectomy of 
the previous allograft (20 out of 23).  
 
Type of dialysis and permanent vascular access at the start of dialysis 
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After the loss of graft function the vast majority of patients started on hemodialysis (n=70), 
only three patients started on peritoneal dialysis, and for another three patients no 
information was available. Two patients decided not to start renal replacement therapy (2 of 
78, 2.6%), one from each the early and late group. A total of 38 of 70 patients (54.3%) started 
dialysis with a native fistula, with 22/37 in the early (59.5%) and 16/33 (48.5%) in the late 
group. Four patients in the early and two patients in the late group started with a functioning 
vascular graft. Therefore, a total of 44/70 (62.8%) started with a permanent vascular access. 
On the contrary, 23/70 (32.8%) started hemodialysis with a catheter. No association was 
found between catheter use and age at time of graft loss, gender, and time of graft loss. 
Patients starting dialysis with a permanent vascular access (fistula or graft) showed a lower 
mortality compared with patients starting with a catheter. Within the first 30 days 5/23 (21.7 
%) of the catheter group and 3/44 (6.8 %) patients with a permanent vascular access died. 
HR of a proportional cox model adjusted for age, early or late graft failure and diabetes 
showed lower mortality for patients with a permanent vascular access compared to catheter, 
HR was 0.32 (CI 95%  0.12-0.83, p-value 0.019).    
  
Immunosuppression at the time of dialysis initiation and thereafter 
The number of immunosuppressive drugs are illustrated in Figures 6 and 7. In Figure 6 the 
number of immunosuppressive drugs for patients with and without nephrectomy at the 
selected point of time after graft loss are shown. The majority of patients (68.6 %) with an 
allograft in place were on three immunosuppressants at the time of allograft loss (including 
corticosteroids). Thereafter the number of immunosuppressants was reduced to two, mostly 
corticosteroids combined with one other immunosuppressant. There was no difference in 
the early and late graft loss group, regarding the strategy of reduction of 
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immunosuppressants.  In 4 of the 78 patients, information about immunosuppressive drugs 
were missing.      
After nephrectomy the immunosuppression was reduced to either no immunosuppressants 
(73% patients) or corticosteroids only (21% patients). Few nephrectomized patients (6%) 
remained on a second immunosuppressive drug one year after graft loss.  
 
Discussion 
As the protocols for treatment of patients after allograft loss vary widely and little data is 
available from outside the US, we performed this analysis from the STCS. Over a period of 
6.5 years in which 1499 patients received a renal allograft, a total of 78 grafts were lost. This 
is comparable to the results published in the USRDS (with 7% in cadaveric donor recipients 
and 3% of the living donor recipients, USRDS, 2016). A recent study of 2447 kidney 
transplantations found that 42 patients died and 67 (2.7%) lost the graft within a year. The 
number of early losses 67 of 2447 (2.7%) was very similar to our study (43 of 1449, 2.8%) 
[5]. 
A striking finding was the high early mortality in our cohort, with 6 out of 41 patients in the 
early group and 5 out of 37 in the late group. Gill and colleagues described the mortality of 
patients losing a graft in a cohort transplanted between 1995 and 2003 and compared them 
with patients on the waiting list, as well as those immediately after transplantation [4]. The 
death rates were higher in DAGL patients as compared to patients after the major surgery 
of transplantation (17.9/100 patient-years versus 8.2/100) and was lowest in patients on the 
waiting list.  
An unexpected finding was that the relative mortality was very similar between patients 
losing the allograft early (i.e. within one year) and late (i.e. after one year). We would have 
12 
 
expected that the risk of dying after a late allograft loss would be associated with a higher 
mortality (for various reasons like increased age, time on immunosuppression). This is an 
important finding as it points towards the danger of the transfer per se and not patient factors. 
Our data therefore confirm the high early mortality in these patients in a recent cohort and 
the need for intervention studies to reduce this high mortality. 
The vast majority of patients started with hemodialysis after allograft loss. Starting with a 
native fistula has the lowest morbidity and mortality in incident hemodialysis patients [6]. 
Unfortunately, there is very little information available about the type of vascular access in 
DAGL patients. About 55% of our patients started with a native fistula. The percentage was 
higher in patients who lost the graft within a year as compared to patients who lost the 
allograft after one year (59.5% versus 48,5%). In one recent study of 61 patients who 
returned to hemodialysis, 76% were described to have a native fistula. As an early loss of a 
graft is an unexpected event, the fistulas were likely still in place from the period before 
transplantation. Unfortunately, we have not documented whether a fistula was still in place 
at the time of graft loss in our cohort (and we are not aware of data from the literature).  
Unexpectedly, the number of native fistulae was even lower in the patients with a late 
allograft loss and the number of catheters increased significantly. This was particularly the 
case for the number of patients starting with a tunneled catheter (3% in the early and 18% 
in the late group). This indicates a poor pre-dialysis management in the current cohort in 
patients losing the graft after one year. Consistently, a recent comparison between DAGL 
patients and incident dialysis patients points towards a poor pre-dialysis care, as DAGL 
patients had lower bicarbonate, higher phosphate, higher blood pressure, lower albumin and 
were more likely to be hospitalized after dialysis initiation [7].  
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An important finding was that a permanent vascular access (fistula or graft) was associated 
with a significantly lower mortality (HR=0.32, CI 95%:0.12-0.83, p-value 0.019). Therefore, 
an increased use of permanent vascular accesses might be a way to decrease the high 
mortality. In our experience the loss of allograft function in the late stages of graft failure is 
difficult to predict and often an unexpected event (e.g. infection) leads to uremic symptoms 
and necessity of dialysis.  Therefore, the timing of discussions about dialysis with an allograft 
recipient needs to be revisited. Importantly, it should be stated that pre-dialysis information 
should not be misinterpreted as giving up the allograft. Efforts of prolonging graft function 
always need to be in parallel with a detailed predialysis work up. Nephrology centres in 
which the care for renal allograft recipients is separated from the predialysis clinic, need to 
rethink the management of allograft recipients with poor allograft function. 
In our cohort, only three patients started peritoneal dialysis, which is below the countrywide 
average of incident patients of about 10%. Two detailed analyses from registries from 
Canada [8] and from the US [9] demonstrated a similar outcome after starting peritoneal 
dialysis as compared to hemodialysis after graft loss. Therefore, both are viable 
opportunities and the barriers for PD use need to be addressed. It is well described that a 
good predialysis information increases the use of PD [10]. 
How to proceed with immunosuppression after the loss of an allograft is an important 
question in daily practice. Infections, malignant disease and costs argue for a reduction of 
immunosuppression [11].  Residual renal function, prevention of immunization and 
prevention of so-called graft intolerance syndrome are arguments to keep 
immunosuppression in place. 
A survey scrutinized the practice in the US [12]. It illustrated that there were no standards 
on how to treat DAGL patients, with 75% of the responders handling immunosuppression 
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on an individual decision by the nephrologist in charge. The immunosuppression was rapidly 
tapered (mostly starting with the calcineurin inhibitor) [12]. 80% were free of 
immunosuppression after one year. This is in strong contrast to our swiss cohort. The 
majority started dialysis with a triple immunosuppression. About 75% of the patients 
remained on at least two, the remaining on one immunosuppressive drug. Only after a 
nephrectomy the immunosuppression was further reduced.  
Also there is no good evidence in the literature about the immunosuppression needed to 
prevent loss of residual renal function, most centers leave some immunosuppression until 
residual renal function has subsided [13]. In Switzerland the combination of steroids and 
antimetabolites is most commonly used in this situation. Using prolonged 
immunosuppression can reduce the risk of immunization by about 40% [14]. Furthermore, 
symptoms from graft intolerance syndrome can be avoided, which would result in allograft 
nephrectomy. In patients not weaned from immunosuppression the rate of hospitalization 
due to infections increases [15]. 
An allograft nephrectomy has significant morbidity and mortality, but allows reduction of 
immunosuppression afterwards without the risk of graft intolerance syndrome [16]. The main 
indication for  an allograft nephrectomy are symptoms of graft intolerance syndrome, 
particularly not responding to immunosuppression [14]. Allograft nephrectomies are 
regularly performed in patients losing grafts early. The impact of nephrectomy on outcome 
like overall mortality and survival of the succeeding graft is difficult to assess due to the 
interdependence of these factors. Register data suggest an improved survival in patients 
with allograft nephrectomy but retransplantation is higher in these patients [17]. In one study 
nephrectomy was associated with a decreased mortality in patients with late allograft loss, 
but not in patients with early loss [18].  
15 
 
A recent meta-analysis which included 1008 patients from 8 studies showed that the 
nephrectomy group had a longer time interval to retransplantation and a higher rate of 
positive panel reactive antibody (PRA > 10%) before retransplantation [19]. No differences 
were observed in serum creatinine one year after retransplantation, one-year graft survival 
rates and one-year patient survival rates. Therefore, no benefit of allograft nephrectomy 
could be illustrated. 
Our cohort describes major differences between the practices in the US and in Switzerland. 
Prolonged immunosuppression and liberal use of transplant nephrectomies are general 
practice in Switzerland. The data illustrate an important lack of evidence to guide the 
treatment in this important phase. Questions have to be addressed in future studies. For 
patients on the transplant list the benefits and risks of a nephrectomy has to be evaluated. 
Similarly, in asymptomatic patients who will not be retransplanted slow tapering needs to be 
tested. 
Our data call for randomized controlled trials to improve our knowledge for this important 












1. Lacson E, Jr., Wang W, DeVries C, et al. Effects of a nationwide predialysis educational program on 
modality choice, vascular access, and patient outcomes. American journal of kidney diseases : the official journal 
of the National Kidney Foundation 2011;58(2):235-242 
2. Winkelmayer WC, Mehta J, Chandraker A, et al. Predialysis nephrologist care and access to kidney 
transplantation in the United States. Am J Transplant 2007;7(4):872-879 
3. Aniort J, Kaysi S, Garrouste C, et al. CKD complications in kidney-transplanted patients going back to 
dialysis: impact on patients outcomes. J Nephrol 2018;31(1):147-155 
4. Gill JS, Rose C, Pereira BJ, et al. The importance of transitions between dialysis and transplantation in 
the care of end-stage renal disease patients. Kidney Int 2007;71(5):442-447 
5. van de Luijtgaarden MW, Jager KJ, Segelmark M, et al. Trends in dialysis modality choice and related 
patient survival in the ERA-EDTA Registry over a 20-year period. Nephrology, dialysis, transplantation : official 
publication of the European Dialysis and Transplant Association - European Renal Association 2016;31(1):120-
128 
6. Ravani P, Palmer SC, Oliver MJ, et al. Associations between Hemodialysis Access Type and Clinical 
Outcomes: A Systematic Review. J Am Soc Nephrol 2013;24(3):465-473 
7. Liakopoulos V, Roumeliotis S, Gorny X, et al. Oxidative Stress in Patients Undergoing Peritoneal Dialysis: 
A Current Review of the Literature. Oxidative medicine and cellular longevity 2017;2017:3494867 
8. Perl J, Hasan O, Bargman JM, et al. Impact of dialysis modality on survival after kidney transplant failure. 
Clin J Am Soc Nephrol 2011;6(3):582-590 
9. Perl J, Dong J, Rose C, et al. Is dialysis modality a factor in the survival of patients initiating dialysis after 
kidney transplant failure? Perit Dial Int 2013;33(6):618-628 
10. Manns BJ, Taub K, Vanderstraeten C, et al. The impact of education on chronic kidney disease patients' 
plans to initiate dialysis with self-care dialysis: a randomized trial. Kidney Int 2005;68(4):1777-1783 
11. Sommerer C, Konstandin M, Dengler T, et al. Pharmacodynamic monitoring of cyclosporine a in renal 
allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of 
recurrent infections and malignancies. Transplantation 2006;82(10):1280-1285 
12. Bayliss GP, Gohh RY, Morrissey PE, et al. Immunosuppression after renal allograft failure: a survey of US 
practices. Clin Transplant 2013;27(6):895-900 
13. Elmahi N, Csongradi E, Kokko K, et al. Residual renal function in peritoneal dialysis with failed allograft 
and minimum immunosuppression. World J Transplant 2013;3(2):26-29 
14. Augustine JJ, Woodside KJ, Padiyar A, et al. Independent of nephrectomy, weaning immunosuppression 
leads to late sensitization after kidney transplant failure. Transplantation 2012;94(7):738-743 
15. Woodside KJ, Schirm ZW, Noon KA, et al. Fever, infection, and rejection after kidney transplant failure. 
Transplantation 2014;97(6):648-653 
16. Akoh JA. Transplant nephrectomy. World J Transplant 2011;1(1):4-12 
17. Ayus JC, Achinger SG, Lee S, et al. Transplant nephrectomy improves survival following a failed renal 
allograft. J Am Soc Nephrol 2010;21(2):374-380 
18. Johnston O, Rose C, Landsberg D, et al. Nephrectomy after transplant failure: current practice and 
outcomes. Am J Transplant 2007;7(8):1961-1967 
19. Wang K, Xu X, Fan M, et al. Allograft nephrectomy vs. no-allograft nephrectomy for renal 
transplantation: a meta-analysis. Clin Transplant 2016;30(1):33-43 
 
 





Table 1: Baseline characteristics of the study cohort 
 
Patients without allograft 
loss 
Patients with allograft loss 
Number of patients 1421 78 
Number of males (%) 906 (63.8) 57 (73.1) 
Age at Transplantation (years, 
median (IQR)) 
54 (44.6) 57 (44.7) 
Observation time days since 
Transplantation (median, IQR) 
1445 (729, 1907) 1191 (447, 2257) 
First Allograft (%) 1197 (84.2) 56 (71.8) 
Re-Transplantation (%) 224 (15.8) 22 (28.2) 
Donor 
  
Brain dead (%) 736 (51.8) 60 (77) 
Living (%) 637 (44.8) 16 (20.5) 
Non-heart-beating donor (%) 48 (3.4) 2 (2.5) 
Dialysis before transplantation 
  
HD (%) 969 (68.2) 64 (82.1) 
PD (%) 199 (14) 9 (11.5) 
Pre-emptive (%) 252 (17.7) 5 (6.4) 
Unknown (%) 1 (0.1) 0 
Etiology (number, %) 
  
Glomerulonephritis / Vasculitis  433 (30.5) 26 (33.3) 
Polycystic kidney disease 282 (19.9) 12 (15.4) 
Hypertensive / renovascular 
nephrosclerosis 
183 (12.9) 11 (14.1) 
Diabetic nephropathy 116 (8.2) 5 (6.4) 
Obstructive nephropathy / Reflux 
/ Pyelonephritis  
85 (6) 4 (5,1) 
Hereditary kidney disease other 
than polycystic kidney disease 
45 (3.2) 2 (2.6) 
Interstitial nephritis, not hereditary 46 (3.2) 2 (2.6) 
Congenital disease / 
malformation 
40 (2.8) 3 (3.9) 
Other 344 (24.2) 24 (30.8) 
Comorbidities 
  
Skin cancer 85 (6) 3 (3.9) 
Cancer other than skin 152 (10.7) 13 (16.7) 
Cardiopulmonary diseases 709 (49.9) 47 (60.3) 
Infectious diseases 303 (21.3) 17 (21.8) 










within one year 
Allograft loss 
after one year 
Number of patients 78 41 (53) 37 (47) 
Number of males (%) 57 (73) 30 (73) 27 (73) 
Age at transplantation in years 
(median (IQR)) 
57 (46, 66) 60 (51, 67) 50 (34, 64) 
Observation time in days since 
graft loss (median, IQR) 
711 (323, 1364) 446 (137, 925) 790 (441, 
1468) 
Time between transplantation 
and graft loss in days (median, 
IQR) 
300 (21, 864) 28 (3, 130) 923 (501, 
1404) 
Number of patients with allograft 
loss within 30 days (%) 
21 (27) 21 (27) 
 
Relisting n (%) 
   
No 8 (10.3) 6 (14.6) 2 (5.4) 
Yes 26 (33.3) 9 (22.0) 17 (46.0) 





Table 3: Causes of allograft nephrectomy (n = 50) 
 n % 
Infections 12 24 
Rejection 10 20 
BK nephropathy 4 8 
Cancer 1 2 
Other 18 36 





Table 4: Dialysis forms and access after allograft loss 
 
All with allograft 
loss (n = 78) 
Allograft loss within 
one year (n = 41) 
Allograft loss after one 
year (n = 37) 
Hemodialysis 70 37 (90.2) 33 (89.2) 
Native fistula 38 (54.3) 22 (59.5) 16 (48.5) 
Arteriovenous 
Graft 
6 (8.6) 4 (10.8) 2 (6.1) 
Tunneled 
catheter 
7 (10) 1 (2.7) 6 (18.2) 
Non-tunneled 
catheter 




3 (4.2) 1 (2.4) 2 (5.4) 
Peritoneal dialysis 3 2 (4.9) 1 (2.7) 
No renal replacement 
therapy 
2 1 (2.4) 1 (2.7) 
Missing information 
on treatment 



















Figure 1: Study population. 1499 patients received a renal allograft during the observation 
time. 82 allografts were lost during the follow-up period. 4 patients were lost to follow-up. 
Therefore, detailed information was given on 78 patients. 
 
Figure 2: Patient courses after allograft loss (A within one year, B after one year). Each 
patient is illustrated as a horizontal line with the events deaths (D), nephrectomy (N), relisting 
(L) and retransplantation (R) illustrated in the course. 
  
Figure 3: Percentage of patients with events after allograft loss (A in all patients, B with 
allograft loss within one year, C with allograft loss after one year). Note the same early death 
rate in both groups. All but one patient were transplant nephrectomized within a year in the 
early loss group (B), whereas this reached 80% after 2 years in late loss group. 
Figure 4: Survival probability after allograft loss 
Figure 5: Cumulative incidence of allograft nephrectomies. Note that in almost all patients who 
lost the allograft within a year the allograft was removed within half a year after graft loss. 
Overall, about 60% received an allograft nephrectomy.  
  
 Figure 6: Immunosuppression after graft loss. Illustrated are the percentages of patients 
(with and without nephrectomy) according to the number of immunosuppressive drugs. In the 
cohort, the number of immunosuppressive drugs does not change significantly as long as the 
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allograft is in place. Even at the time of allograft loss the majority is still under triple 
immunosuppressive therapy (nr: number, mth: months). 
 Figure 7: Immunosuppressive drugs and glucocorticoid therapy. Illustrated are the number of 
patients according to the number of immunosuppressant. Glucocorticoid use is illustrated. 
Note that the vast majority was on glucocorticoids. Only after nephrectomy the overall number 
of immunosuppressants decreases. 
 
 
